Eleni Giannopoulou

Scopus Publications

The conundrum in diagnosing Maturity-Onset Diabetes of the Young (MODY) in a large German pedigree with early-onset diabetes and a novel HNF1A variant
Eleni Z. Giannopoulou, Abubakar Moawia, Josef Högel, Joanna Lerner, Stefanie Zorn, Christian Denzer, Reiner Siebert, Martin Wabitsch
Molecular and Cellular Pediatrics, 2026
Genetic screening for maturity-onset diabetes of the young (MODY) involves sequencing of the coding regions of known disease-associated genes. We describe the complex and challenging diagnostic journey of a patient with early-onset diabetes with a novel, intronic HNF1A variant likely affecting a branching site. The patient was diagnosed with diabetes at the age of 10 years after incidental hyperglycemia (HbA1c 8.1%, C-peptide 3.0 μg/dl), without polyuria, polydipsia, or weight loss. Type 1 diabetes associated autoantibodies were negative, but the patient had a strong family history of early-onset diabetes (classified as type 1 or type 2 diabetes). Initial genetic testing for HNF4A, GCK, HNF1A, and HNF1B coding regions (including exon/intron boundaries ± 20 bp) and MLPA were negative. Sulfonylureas provided good glycemic control until age 16, when insulin was added. At age 18, an expanded targeted next-generation sequencing (NGS) panel for MODY was also negative. At age 24, whole-exome-sequencing via NGS and additional analysis was conducted, focusing on synonymous and intronic variants, and revealed a heterozygous HNF1A variant (c.327-28A > G;p.?) in the patient and four affected relatives. The variant co-segregated with diabetes, and was predicted to affect splicing via branching site disruption, suggesting pathogenicity. In summary, this case highlights the importance of a comprehensive diagnostic approach that combines clinical, biochemical, and extended genetic evaluation. When MODY is strongly suspected despite negative targeted testing, broader sequencing—including intronic and regulatory regions—should be pursued. Accurate variant interpretation remains essential to prevent misclassification and to optimize diagnosis, treatment, and understanding of the genetic complexity of monogenic diabetes.
Monogenic obesity due to MC4R deficiency: lessons from a multigenerational case
Eleni Z. Giannopoulou, Stefanie Zorn, Melanie Schirmer, Stephanie Brandt-Heunemann, Julia von Schnurbein, Claudia Nestoris, Abubakar Moawia, Reiner Siebert, Christian Denzer, Martin Wabitsch
Molecular and Cellular Pediatrics, 2026
Background Melanocortin 4 receptor (MC4R) deficiency is the most common monogenic cause of obesity, yet remains underdiagnosed. Patients with monogenic obesity often undergo a frustrating diagnostic and therapeutic odyssey of years of ineffective lifestyle interventions before a causal diagnosis is made. We report a four-generation family where genetic testing in a child identified a likely pathogenic MC4R variant also carried by three ancestors. Methods The studied family included a 7-year-old index patient, her mother, grandmother, and great-grandmother with a history of early-onset obesity. Panel sequencing of monogenic obesity genes was performed in the index patient whereas in the relatives targeted analysis of the familial MC4R variant was performed by Sanger sequencing. Results The index patient developed severe obesity by age 2 years, with hyperphagia, tall stature, and dyslipidemia. Despite lifestyle interventions, her body mass index (BMI) continued to increase. At the age of 7 years, genetic panel testing identified a rare monoallelic variant in the MC4R gene c.913C > T; p.Arg305Trp, previously shown to impair receptor function. Treatment with liraglutide (3.0 mg/day) was initiated at age 8 years, resulting in marked reduction in BMI during the first year of treatment. Subsequent genetic testing of family members identified the same variant in her mother, grandmother, and great-grandmother, all of whom had a history of early-onset obesity and related comorbidities, consistent with segregation of the variant within the family. Conclusions This case underscores the importance of early genetic testing in severe childhood obesity to avoid ineffective treatments and enable targeted therapies (e.g., GLP-1 analogues). Diagnosing (likely) pathogenic MC4R variants can also identify at-risk relatives, providing psychological and clinical benefits across generations.
Two-year outcomes after early postnatal high-dose fat-soluble enteral vitamin A supplementation in extremely low birth weight infants: follow-up of the NeoVitaA randomized controlled trial
Martin Poryo, Ludwig Gortner, Johannes Bay, Axel R. Franz, Harald Ehrhardt, Lars Klein, Judith Behnke, Tina Frodermann, Jutta Petzinger, Christoph Binder, Susanne Kirschenhofer, Anja Stein, Britta Hüning, Axel Heep, Eva Cloppenburg, Julia Muyimbwa, Torsten Ott, Julia Sandkötter, Norbert Teig, Susanne Wiegand, Michael Schroth, Andrea Kick, Donald Wurm, Corinna Gebauer, Knud Linnemann, Jochen Kittel, Christian Wieg, Ursula Kiechl-Kohlendorfer, Susanne Schmidt, Ralf Böttger, Wolfgang Thomas, Francisco Brevis Nunez, Antje Stockmann, Thomas Kriebel, Andreas Müller, Daniel Klotz, Patrick Morhart, Donatus Nohr, Hans Konrad Biesalski, Eleni Z. Giannopoulou, Susanne Hilt, Stefan Wagenpfeil, Nadja Haiden, Matthew Rysavy, Christoph Härtel, Christian Ruckes, Anne Ehrlich, Sascha Meyer
Eclinicalmedicine, 2025
Background: The longer-term effects of early high-dose vitamin A to support lung development in preterm infants remain to be clarified. The aim of the NeoVitaA follow-up study was to assess the effects of early postnatal additional high-dose fat-soluble enteral vitamin A supplementation (HD-VitA) vs. placebo (control) for 28 days on respiratory complications and neurodevelopmental outcome in ELBW infants receiving recommended basic vitamin A supplementation, specified as secondary outcome parameters in the NeoVitaA trial. Methods: The trial was approved by the ethics committee of Saarland, Saarbruecken, Germany (file number: 70/2011) as well as by all local ethics committees and the Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM, Bonn, Germany). The NeoVitaA trial was registered with EudraCT (2013-001998-24) and DRKS (DRKS00006541). This follow-up covers secondary endpoints at 12 and 24 months as mentioned in the registration. Follow-up took place between September 2019 and June 2024. Follow-up assessment at 12 and 24 months' corrected age (CA) of infants enrolled in the NeoVitaA-trial included anthropometric data, number of antibiotic treatments, antibiotic treatments for pulmonary infections, hospital admissions, and hospital admissions for pulmonary infections, composite scores of the Bayley Scale of Infant and Toddler Development, second (Bayley-II) or third edition (Baley-III), other medical diagnoses and medical treatments. Findings: Follow-up examinations were available for 759 infants (83.0%). HD-VitA had no effect on number of antibiotics needed for pulmonary infections or number of hospital admissions for pulmonary infections at 12 or 24 months' CA. At 24 months' CA, the median number of antibiotic courses for pulmonary infections was one for both the HD-VitA and control group; the median number of hospital admissions for pulmonary infections per patient was 0 (HD-VitA) and 1 (control).Successful Bayley assessment was completed in 618/759 infants (92 Bayley-II, 526 Bayley-III). The median Mental Development Index score for Bayley-II was 95 vs. 97 (median difference -5.0, 95%-CI [-12.0, 2.0]) and Psychomotor Development Index 96 vs. 92 (median difference 3.0, 95%-CI [-4.0, 8.0]), with intervention and placebo, respectively. The median cognitive composite score for Bayley-III was 95 vs. 95 (median difference 0.0, 95%-CI [-5.0, 0.0]) and motor score was 92 vs. 92 (median difference 0.0, 95%-CI [-4.0, 3.0]), respectively. Interpretation: Early postnatal high-dose enteral fat-soluble vitamin A supplementation in ELBW infants did not affect pulmonary or developmental outcomes at 24 months' CA. Funding: The NeoVitaA trial was funded by the Deutsche Forschungsgemeinschaft ME 3827/1-1/2 and European Clinical Research Infrastructures Network.
Corrigendum to “Two-year outcomes after early postnatal high-dose fat-soluble enteral vitamin A supplementation in extremely low birth weight infants: follow-up of the NeoVitaA randomized controlled trial”
Martin Poryo, Ludwig Gortner, Johannes Bay, Axel R. Franz, Harald Ehrhardt, Lars Klein, Judith Behnke, Tina Frodermann, Jutta Petzinger, Christoph Binder, Susanne Kirschenhofer, Anja Stein, Britta Hüning, Axel Heep, Eva Cloppenburg, Julia Muyimbwa, Torsten Ott, Julia Sandkötter, Norbert Teig, Susanne Wiegand, Michael Schroth, Andrea Kick, Donald Wurm, Corinna Gebauer, Knud Linnemann, Jochen Kittel, Christian Wieg, Ursula Kiechl-Kohlendorfer, Susanne Schmidt, Ralf Böttger, Wolfgang Thomas, Francisco Brevis Nunez, Antje Stockmann, Thomas Kriebel, Andreas Müller, Daniel Klotz, Patrick Morhart, Donatus Nohr, Hans Konrad Biesalski, Eleni Z. Giannopoulou, Susanne Hilt, Stefan Wagenpfeil, Nadja Haiden, Matthew Rysavy, Christoph Härtel, Christian Ruckes, Anne Ehrlich, Sascha Meyer
Eclinicalmedicine, 2025
[This corrects the article DOI: 10.1016/j.eclinm.2025.103495.].
Exploring Metabolic Signatures: Unraveling the Association with Obesity in Children and Adolescents
Diamanto Koutaki, Garyfallia Stefanou, Sofia-Maria Genitsaridi, Eleni Ramouzi, Athanasia Kyrkili, Meropi D. Kontogianni, Eleni Kokkou, Eleni Giannopoulou, Penio Kassari, Evangelia Charmandari
Nutrients, 2025
Background: Childhood obesity is a growing global health concern. Metabolomics, the comprehensive study of metabolites within biological systems, offers a powerful approach to better define the phenotype and understand the complex biochemical alterations associated with obesity. The aim of this systematic review was to summarize current knowledge in the field of metabolomics in childhood obesity and to identify metabolic signatures or biomarkers associated with overweight/obesity (Ov/Ob) and Metabolically Unhealthy Obesity (MUO) in children and adolescents. Methods: We performed a systematic search of Medline and Scopus databases according to PRISMA guidelines. We included only longitudinal prospective studies or randomized controlled trials with ≥12 months of follow-up, as well as meta-analyses of the above that assessed the relation between metabolic signatures related to obesity and Body Mass Index (BMI) or other measures of adiposity in children and adolescents aged 2–19 years with overweight or obesity. Initially, 595 records were identified from PubMed and 1565 from Scopus. After removing duplicates and screening for relevance, 157 reports were assessed for eligibility. From the additional search, 75 new records were retrieved, of which none were eligible for our study. Finally, 7 reports were included in the present systematic review (4 reporting on Ov/Ob and 4 on MUO). Results: The presented studies suggest that the metabolism of amino acids and lipids is primarily affected by childhood obesity. Metabolites like glycoprotein acetyls, the Apolipoprotein B/Apolipoprotein A-1 ratio, and lactate have emerged as potential biomarkers for insulin resistance and metabolic syndrome, highlighting their potential value in clinical applications. Conclusions: There is a need for future longitudinal studies to assess metabolic changes over time, interventional studies to evaluate the efficacy of therapeutic strategies, and large-scale population studies to explore metabolic diversity across different demographics. Our findings reveal specific biomarkers in the amino acid and lipid pathway that may serve as early indicators of childhood obesity and its associated cardiometabolic complications.
Early postnatal high-dose fat-soluble enteral vitamin A supplementation for moderate or severe bronchopulmonary dysplasia or death in extremely low birthweight infants (NeoVitaA): a multicentre, randomised, parallel-group, double-blind, placebo-controlled, investigator-initiated phase 3 trial
Sascha Meyer, Johannes Bay, Axel R Franz, Harald Erhardt, Lars Klein, Jutta Petzinger, Christoph Binder, Susanne Kirschenhofer, Anja Stein, Britta Hüning, Axel Heep, Eva Cloppenburg, Julia Muyimbwa, Torsten Ott, Julia Sandkötter, Norbert Teig, Susanne Wiegand, Michael Schroth, Andrea Kick, Donald Wurm, Corinna Gebauer, Knud Linnemann, Jochen Kittel, Christian Wieg, Ursula Kiechl-Kohlendorfer, Susanne Schmidt, Ralf Böttger, Wolfgang Thomas, Francisco Brevis Nunez, Antje Stockmann, Thomas Kriebel, Andreas Müller, Daniel Klotz, Patrick Morhart, Donatus Nohr, Hans Konrad Biesalski, Eleni Z Giannopoulou, Susanne Hilt, Martin Poryo, Stefan Wagenpfeil, Nadja Haiden, Christian Ruckes, Anne Ehrlich, Ludwig Gortner, Rahel Schuler, Birgit Kampschulte, Annesuse Schmidt, Svilen Atanasov, Mark Dzietko, Sebastian Prager, Ioana Bialas, Petra Kramps, Sarah Beckmann, Jürgen Seidenberg, Katja Majosthusmann, Jenny Potratz, Alijda van den Heuvel, Maria Tekaat, Susanne Dettmers, Marie-Therese Unterweger, Heike Nowak, Jens Möller, Ulrich Thome, Jörg Arand, Beate Luger, Christian A Maiwald, Martin Heideking, Matthias Heckmann, Annette Keller-Wacherbauer, Holger Michel, Tanja Karen, Anna Schmid, Yasmin Pellkofer, Elke Griesmaier, Orsolya Genzel-Boroviczeny, Raquel Mata Fernandez, Stefan Avenarius, Andrea Czoske, Christoph Block, Simone Schwarz, Andreas Jenke, Tamara Grass, Martin Kuntz, Fabian Fahlbusch, Johannes Pöschl, Jule Metzger, Sebastian Ronellenfitsch, Thomas Schaible, Julia Reinhard, Sonja Trepels-Kottek, Jacqueline Bauer, Egbert Herting, Wolfram Henn, Annette Laupert, Rebecca Jathe
Lancet Respiratory Medicine, 2024
Long term effects of aromatase inhibitor treatment in patients with aromatase excess syndrome
Eleni Z. Giannopoulou, Stephanie Brandt, Stefanie Zorn, Christian Denzer, Julia von Schnurbein, Maki Fukami, Alexander Kaiser, Martin Schmidt, Martin Wabitsch
Frontiers in Endocrinology, 2024
IntroductionAromatase excess syndrome (AEXS) is a rare, autosomal dominant disorder, characterized by enhanced aromatization of androgens and estrogen excess. In males it is characterized by pre-/peripubertal gynecomastia, hypogonadotropic hypogonadism, advanced bone age and short adult height. Only a few female patients have been described so far.MethodsWe report on a family with four members with AEXS and present the long-term effects of aromatase inhibitor use in three of them. Genetic analysis showed a monoallelic 0.3-Mb deletion in 15q21, involving parts of CYP19A1, GLDN and DMXL2 in all four patients with AEXS.ResultsThe index patient (male, 8 years old) presented with gynecomastia and accelerated growth and bone age. With start of puberty, estradiol levels increased, while testosterone levels remained low. Gynecomastia progressed and a mastectomy was performed twice. Presuming AEXS, a therapy with letrozole was initiated at the age of 19 years. Low-dose letrozole treatment was associated with an increase in testicular volume, increase in virilization and improvement in physical strength and libido. His brother (age 3 years) presented with accelerated growth and bone age. Treatment with letrozole, which was started at the age of 7 years, resulted in achieving an adult height of 179 cm and prevented the appearance of gynecomastia. His sister (age 6 years), who presented with premature thelarche and accelerated growth and bone age, was treated with an estrogen receptor modulator and a GnRH analog followed by letrozole treatment. Menarche occurred at age 13.5 years and adult height was 158 cm. Their father had an early, accelerated growth with an adult height of 171 cm, a delayed puberty and no gynecomastia. In vitro studies provided evidence for involvement of aromatase induction in atypical cells and an increased range of potential mechanisms regulating aromatase activity due to the presence of the mutated allele.DiscussionIn conclusion, we observed a phenotypic variability within family members with AEXS carrying the same CYP19A1 microdeletion. When started early, treatment with letrozole was found to prevent the development of gynecomastia and increase adult height in one patient. In adult life, low-dose letrozole treatment resulted in improved physical strength and libido in the index patient.
Genetic Obesity in Children: Overview of Possible Diagnoses with a Focus on SH2B1 Deletion
Eleni Z. Giannopoulou, Stefanie Zorn, Melanie Schirmer, Gloria Herrmann, Sabine Heger, Thomas Reinehr, Christian Denzer, Hannah Rabenstein, Morten Hillmer, Nadine Sowada, Reiner Siebert, Julia von Schnurbein, Martin Wabitsch
Hormone Research in Paediatrics, 2022
Introduction: Genetic obesity is rare and quite challenging for pediatricians in terms of early identification. Src-homology-2 (SH2) B adapter protein 1 (SH2B1) is an important component in the leptin-melanocortin pathway and is found to play an important role in leptin and insulin signaling and therefore in the pathogenesis of obesity and diabetes. Microdeletions in chromosome 16p11.2, encompassing the SH2B1 gene, are known to be associated with obesity, insulin resistance, hyperphagia, and developmental delay. The aim of our study is to report on a case series of young individuals with 16p11.2 microdeletions, including the SH2B1 gene, and provide detailed information on body mass index (BMI) development and obesity-associated comorbidities. In this way, we want to raise awareness of this syndromic form of obesity as a differential diagnosis of genetic obesity. Methods: We describe the phenotype of 7 children (3 male; age range: 2.8–18.0 years) with 16p11.2 microdeletions, encompassing the SH2B1 gene, and present their BMI trajectories from birth onward. Screening for obesity-associated comorbidities was performed at the time of genetic diagnosis. Results: All children presented with severe, early-onset obesity already at the age of 5 years combined with variable developmental delay. Five patients presented with elevated fasting insulin levels, 1 patient developed diabetes mellitus type 2, 4 patients had dyslipidemia, and 4 developed nonalcoholic fatty-liver disease. Discussion/Conclusion: Chromosomal microdeletions in 16p11.2, including the SH2B1 gene, in children are associated with severe, early-onset obesity and comorbidities associated with insulin resistance. Early genetic testing in suspicious patients and early screening for comorbidities are recommended.
Transient neonatal diabetes due to a disease causing novel variant in the ATP-binding cassette subfamily C member 8 (ABCC8) gene unmasks maturity-onset diabetes of the young (MODY) diabetes cases within a family
Eleni Z Giannopoulou, Olga Ovcarov, Elisa De Franco, Fabian Kassberger, Susanne Nusser, Marie Celine Otto, Christian Denzer, Martin Wabitsch
Journal of Pediatric Endocrinology and Metabolism, 2021
Objectives Neonatal diabetes mellitus (NDM) is a rare monogenic diabetes form, occurring mainly from ATP-binding cassette subfamily C member 8 (ABCC8) and KCNJ11 mutations. ABCC8 mutations have also been found to cause adult-onset diabetes. What is new?: •Novel ABCC8 mutation in an NDM case •Heterogeneous clinical presentation of diabetes and response to sulfonylurea therapy among family members with the same ABCC8 mutation. Case presentation We report the case of a newborn with NDM and a heterozygous ABCC8 novel variant (c.3835G>A), successfully treated with sulfonylurea. The same ABCC8 variant was found in two other family members, already treated for type 2 diabetes. Conclusions This case demonstrates the variable phenotypic presentation of diabetes due to a novel ABCC8 mutation (c.3835G>A), ranging from transient NDM to adult-onset, insulin-demanding diabetes, among family members. Genetic testing in young individuals with a strong family history of diabetes, presenting with non-autoimmune diabetes is recommended as it can determine prognosis and treatment of affected family members.
Subclinical arterial damage in children and adolescents with type 1 diabetes: A systematic review and meta-analysis
Eleni Z. Giannopoulou, Ioannis Doundoulakis, Christina Antza, Athanasios Christoforidis, Anna Bettina Haidich, Vasilios Kotsis, Stella Stabouli
Pediatric Diabetes, 2019
Type 1 diabetes is an important risk factor for the development of cardiovascular disease. Pulse wave velocity (PWV) and carotid intima‐media thickness (cIMT) measurements are well recognized as independent predictors for future cardiovascular disease. The aim of the present study was to systematically review the literature and conduct a meta‐analysis assessing measures of subclinical arterial damage in children and adolescents with type 1 diabetes in comparison to healthy controls.
Efficacy of vildagliptin for prevention of postpartum diabetes in women with a recent history of insulin-requiring gestational diabetes: A phase II, randomized, double-blind, placebo-controlled study
Sandra Hummel, Andreas Beyerlein, Markus Pfirrmann, Anna Hofelich, Daniela Much, Susanne Hivner, Melanie Bunk, Melanie Herbst, Claudia Peplow, Markus Walter, Denise Kohn, Nadine Hummel, Jürgen Kratzsch, Michael Hummel, Martin Füchtenbusch, Joerg Hasford, Anette-G. Ziegler, Markus Walter, Heike Börschmann, Sophia Ebe, Eleni Giannopoulou, Minna Harsunen, Veronika Hofbauer, Anna Hofelich, Andrea Schuppenies, Maike Wallner, David Wiesenäcker, Stephanie Zillmer, Melanie Bunk, Melanie Herbst, Susanne Hivner, Lorenz Lachmann, Daniela Much, Claudia Peplow, Joerg Hasford, Markus Pfirrmann, Rüdiger Landgraf, Karl-Theo Maria Schneider, Elisabeth André, Viktoria Janke, Andreas Beyerlein, Sandra Hummel, Ezio Bonifacio, Martin Füchtenbusch, Michael Hummel, Denise Kohn
Molecular Metabolism, 2018
Novel Mutation in an Infant with Niemann-Pick Disease Type A/B
E. Giannopoulou, R. Furtwängler, F. Bürger, D. Schöndorf, L. Gortner, S. Meyer
Klinische Padiatrie, 2016
Islet autoantibody phenotypes and incidence in children at increased risk for type 1 diabetes
Eleni Z. Giannopoulou, Christiane Winkler, Ruth Chmiel, Claudia Matzke, Marlon Scholz, Andreas Beyerlein, Peter Achenbach, Ezio Bonifacio, Anette-G. Ziegler
Diabetologia, 2015
Solitary Median Maxillary Central Incisor
Eleni Z. Giannopoulou, Tilman Rohrer, Paul Hoffmann, Umut Yilmaz, Ludwig Gortner, Sascha Meyer
Journal of Pediatrics, 2015
Vasopressin in arterial hypotension in extremely low birth weight infants
Sascha Meyer, Eleni Z. Giannopoulou
Journal of Pediatrics, 2015
A dangerous ride: A case of traumatic splenic rupture
Eleni Z. Giannopoulou, Ludwig Gortner, Clemens-Magnus Meier, Sascha Meyer
Journal of Pediatrics, 2015
Progression from single to multiple islet autoantibodies often occurs soon after seroconversion: implications for early screening
Ruth Chmiel, Eleni Z. Giannopoulou, Christiane Winkler, Peter Achenbach, Anette-Gabriele Ziegler, Ezio Bonifacio
Diabetologia, 2015
Erratum to: Feature ranking of type 1 diabetes susceptibility genes improves prediction of type 1 diabetes [Diabetologia, (2014), DOI 10.1007/s00125-014-3362-1]
Christiane Winkler, Jan Krumsiek, Florian Buettner, Christof Angermüller, Eleni Z. Giannopoulou, Fabian J. Theis, Anette-Gabriele Ziegler, Ezio Bonifacio
Diabetologia, 2015
Cellular and humoral coagulation profiles and occurrence of IVH in VLBW and ELWB infants
Perrine Duppré, Harald Sauer, Eleni Z. Giannopoulou, Ludwig Gortner, Holger Nunold, Stefan Wagenpfeil, Jürgen Geisel, Bernhard Stephan, Sascha Meyer
Early Human Development, 2015
Feature ranking of type 1 diabetes susceptibility genes improves prediction of type 1 diabetes
Christiane Winkler, Jan Krumsiek, Florian Buettner, Christof Angermüller, Eleni Z. Giannopoulou, Fabian J. Theis, Anette-Gabriele Ziegler, Ezio Bonifacio
Diabetologia, 2014
Prevalence of vitamin D deficiency in pre-type 1 diabetes and its association with disease progression
Jennifer Raab, Eleni Z. Giannopoulou, Simone Schneider, Katharina Warncke, Miriam Krasmann, Christiane Winkler, Anette-Gabriele Ziegler
Diabetologia, 2014
Effect of a single autologous cord blood infusion on beta-cell and immune function in children with new onset type 1 diabetes: A non-randomized, controlled trial
Eleni Z Giannopoulou, Ramona Puff, Andreas Beyerlein, Irene von Luettichau, Heike Boerschmann, Desmond Schatz, Mark Atkinson, Michael J Haller, Dietmar Egger, Stefan Burdach, Anette-Gabriele Ziegler
Pediatric Diabetes, 2014
Reduced blood leukocyte and neutrophil numbers in the pathogenesis of type 1 diabetes
M. Harsunen, R. Puff, O. D'Orlando, E. Giannopoulou, L. Lachmann, A. Beyerlein, A. von Meyer, A.-G. Ziegler
Hormone and Metabolic Research, 2013
Gestational diabetes: The PINGUIN-Study of the diabetes research group TU Munich
Medizinische Welt, 2012
A strategy for combining minor genetic susceptibility genes to improve prediction of disease in type 1 diabetes
C Winkler, J Krumsiek, J Lempainen, P Achenbach, H Grallert, E Giannopoulou, M Bunk, F J Theis, E Bonifacio, A-G Ziegler
Genes and Immunity, 2012
Two-year cyclic infusion of pamidronate improves bone mass density and eliminates risk of fractures in a girl with osteoporosis due to Hajdu-Cheney syndrome
Minerva Endocrinologica, 2012
Insulin resistance is associated with at least threefold increased risk for prothrombotic state in severely obese youngsters
Assimina Galli-Tsinopoulou, Ioannis Kyrgios, Ioanna Maggana, Eleni Z. Giannopoulou, Eleni P. Kotanidou, Charilaos Stylianou, Emmanouil Papadakis, Ioannis Korantzis, George Varlamis
European Journal of Pediatrics, 2011
Acquired toxoplasmosis accompanied by facial nerve palsy in an immunocompetent 5-year-old child
Assimina Galli-Tsinopoulou, Ioannis Kyrgios, Eleni Z. Giannopoulou, Styliani Gourgoulia, Ioanna Maggana, Elina Katechaki, Dimitrios Chatzidimitriou, Athanasios E. Evangeliou
Journal of Child Neurology, 2010

Eleni Giannopoulou

EDUCATION

RESEARCH, TEACHING, or OTHER INTERESTS

Scopus Publications

RECENT SCHOLAR PUBLICATIONS

MOST CITED SCHOLAR PUBLICATIONS